A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons

Journal of the American Academy of Dermatology

Volumn 72, Issue 3, 2015, Pages 524-534

  Brown, Deanna G ^a   Wilkerson, Eric C ^a   Love, W Elliot ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

anticoagulant; antiplatelet; apixaban; blood thinners; dabigatran; dermatologic surgery; dietary supplements; prasugrel; rivaroxaban; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; FISH OIL; NON PRESCRIPTION DRUG; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTIPLATELET THERAPY; BLEEDING; DERMATOLOGIST; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MONITORING; GARLIC; GINKGO BILOBA; GINSENG; HUMAN; MEDLINE; META ANALYSIS; OUTPATIENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SKIN SURGERY; THROMBOSIS; CHEMICALLY INDUCED; DERMATOLOGY; FOOD DRUG INTERACTION; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RISK ASSESSMENT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DERMATOLOGIC SURGICAL PROCEDURES; DERMATOLOGY; DIETARY SUPPLEMENTS; FOOD-DRUG INTERACTIONS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84925402562     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.10.027     Document Type: Review

References (76)

1. J.S. Bordeaux, K.J. Martires, and D. Goldberg Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications J Am Acad Dermatol 65 2011 576 583
2. R.H. Cook-Norris, J.D. Michaels, and A.L. Weaver Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation J Am Acad Dermatol 65 2011 584 591
3. I. Shimizu, N.J. Jellinek, and R.G. Dufresne Multiple antithrombotic agents increase the risk of postoperative hemorrhage in dermatologic surgery J Am Acad Dermatol 58 2008 810 816
4. K.G. Lewis, and R.G. Dufresne A meta-Analysis of complications attributed to anticoagulation among patients following cutaneous surgery Dermatol Surg 34 2008 160 165
5. E.M. Billingsley, and M.M. Maloney Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents Dermatol Surg 23 1997 381 385
6. C.G. Bunick, and S.Z. Aasi Hemorrhagic complications in dermatologic surgery Dermatol Ther 24 2011 537 550
7. M.J. Stanger, L.A. Thompson, A.J. Young, and H.R. Lieberman Anticoagulant activity of select dietary supplements Nutr Rev 70 2012 107 117
8. S.C. Collins, and R.G. Dufresne Dietary supplements in the setting of Mohs surgery Dermatol Surg 28 2002 447 452
9. C. Kearon, S.R. Kahn, G. Agnelli, S. Goldhaber, G.E. Raskob, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines 8th ed. Chest 133 2008 454S 545S
10. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians evidence-based clinical practice guidelines 8th ed. Chest 133 2008 546S 592S
11. R.C. Becker, T.W. Meade, and P.B. Berger The primary and secondary prevention of coronary artery disease. American College of Chest Physicians evidence-based clinical practice guidelines 8th ed. Chest 133 2008 776S 814S
12. D.N. Salem, P.T. O'Gara, C. Madias, and S.G. Pauker Valvular and structural heart disease. American College of Chest Physicians evidence-based clinical practice guidelines 8th ed. Chest 133 2008 593S 629S
13. Coumadin [full prescribing information]. Bristol-Myers Squibb Pharma Co, Princeton, NJ; 2011. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/009218s107lbl.pdf. Accessed May 5, 2012.
14. L. Borris Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty Arch Orthop Trauma Surg 130 2010 583 589
15. I.Y. Gong, U.I. Schwarz, and N. Crown Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation PLoS One 6 2011 e27808
16. J. Ansell, J. Hirsh, and E. Hylek Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians evidence-based clinical practice guidelines 8th ed. Chest 133 2008 160S 198S
17. E. Nutescu, I. Chuatrisorn, and E. Hellenbart Drug and dietary interactions of warfarin and novel oral anticoagulants: an update J Thromb Thrombolysis 31 2011 326 343
18. D. Garcia, W. Ageno, and H. Bussey Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 1: prevention Am J Hematol 84 2009 579 583
19. C.C. Otley Perioperative evaluation and management in dermatologic surgery J Am Acad Dermatol 54 2006 119 127
20. Pradaxa [full prescribing information]. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT; 2014. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022512s018lbl.pdf. Accessed May 26, 2014.
21. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
22. J. Oldgren, M. Alings, and H. Darlus Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial Ann Intern Med 155 2011 660 667
23. J. Oldgren, A. Budaj, and C.B. Granger Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
24. L. Wallentin, S. Yusuf, and M. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
25. J.W.M. Cheng, and H. Vu Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders Clin Ther 34 2012 766 787
26. J.P. Bota, K.G. LeBlanc, and D.J. Sheehan Dabigatran etexilate: clinical implications in dermatologic surgery Dermatol Surg 38 2012 675 676
27. W.E. Dager Developing a management plan for oral anticoagulant reversal Am J Health Syst Pharm 70 Suppl 2013 S21 S31
28. Q. Ma Development of oral anticoagulants Br J Clin Pharmacol 64 3 2007 263 265
29. J.D. Douketis Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management Curr Pharm Des 16 31 2010 3436 3441
30. Xarelto [full prescribing information]. Janssen Ortho LLC, Gurabo, PR; 2014. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022406s009lbl.pdf. Accessed May 26, 2014.
31. C. Becattini, M.C. Vedovati, and G. Agnelli Old and new anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature Thromb Res 129 2012 392 400
32. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
33. The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
34. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 26 2012 2499 2510
35. A. Lai, N. Davidson, S.W. Galloway, and J. Thachil Perioperative management of patients on new oral anticoagulants Br J Surg 101 2014 742 749
36. Eliquis [full prescribing information]. Bristol-Myers Squibb Co, Princeton, NJ; 2014. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202155s003lbl.pdf. Accessed May 26, 2014.
37. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 9 2011 806 817
38. V.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
39. H.C. Diener, J. Eikelboom, and S. Connolly Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischemic attack: a predefined subgroup analysis from AVERROES, a randomized trial Lancet Neurol 11 2012 225 231
40. S. Schulman, and M. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
41. A. Michelson Advances in antiplatelet therapy Hematology Am Soc Hematol Educ Program 2011 2011 62 69
42. Antithrombotic Trialists' Collaboration Collaborative meta-Analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
43. J.S. Berger, D.L. Brown, and R.C. Becker Low-dose aspirin in patients with stable cardiovascular disease: a meta-Analysis Am J Med 121 2008 43 49
44. A. Bartolucci, M. Tendera, and G. Howard Meta-Analysis of multiple primary prevention trials of cardiovascular events using aspirin Am J Cardiol 107 2011 1796 1801
45. O. Yousuf, and D.L. Bhatt The evolution of antiplatelet therapy in cardiovascular disease Nat Rev Cardiol 8 2011 547 559
46. R. Hall, and C.D. Mazer Antiplatelet drugs: a review of their pharmacology and management in the perioperative period Anesth Analg 112 2011 292 318
47. CAPRIE Steering Committee A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) Lancet 348 1996 1329 1339
48. Plavix [full prescribing information]. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bridgewater, NJ; 2013. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/020839s058lbl.pdf. Accessed May 26, 2014.
49. T. Jernberg, C.D. Payne, and K.J. Winters Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Eur Heart J 27 2006 1166 1173
50. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2007 2001 2015
51. Effient [full prescribing information]. Eli Lilly and Co, Indianapolis, IN; 2013. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022307s010lbl.pdf. Accessed May 26, 2014.
52. R.F. Storey Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors Thromb Haemost 105 Suppl 1 2011 S75 S81
53. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
54. C. Dib, E.B. Hanna, and M.S. Abu-Fadel A new era for antiplatelet therapy in patients with acute coronary syndrome Am J Med Sci 340 5 2010 407 411
55. Aggrenox [full prescribing information]. Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT; 2012. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/020884s030lbl.pdf. Accessed September 23, 2012.
56. The ESPRIT Study Group Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial Lancet 367 2006 1665 1673
57. S.M. Dinehart, and L. Henry Dietary supplements: altered coagulation and effects on bruising Dermatol Surg 31 2005 819 826
58. P.D. Shenefelt Herbal treatment for dermatologic disorders. Chapter 18 I.F.F. Benzie, S. Wachtel-Galor, Herbal medicine: biomolecular and clinical aspects 2nd ed. 2011 CRC Press Boca Raton (FL) Available from: URL: http://www.ncbi.nlm.nih.gov/books/NBK92761/. Accessed September 23, 2012
59. F. Borrelli, R. Capasso, and A. Izzo Garlic (Allium sativum): adverse effects and drug interactions in humans Mol Nutr Food Res 51 2007 1386 1397
60. S.A. Mousa Antithrombotic effects of naturally derived products on coagulation and platelet function Methods Mol Biol 663 2010 229 240
61. J.Y. Yu, Y. Jin, and J. Lee Antiplatelet and antithrombotic activities of Korean red ginseng Arch Pharm Res 29 10 2006 898 903
62. A.L.F. Chan, H.W.C. Leung, J. Wu, and T. Chien Risk of hemorrhage associated with co-prescriptions for Gingko biloba and antiplatelet or anticoagulant drugs J Altern Complement Med 17 6 2011 513 517
63. W.S. Harris, S. Silveira, and C.A. Dujovne The combined effects of N-3 fatty acids and aspirin on hemostatic parameters in man Thromb Res 57 1990 517 526
64. M.J. Haut, and D.H. Cowan The effect of ethanol on hemostatic properties of human blood platelets Am J Med 56 1974 22 33
65. R. Rubin Effect of ethanol on platelet function Alcohol Clin Exp Res 23 6 1999 1114 1118
66. L. Lacoste, J. Hung, and J.Y.T. Lam Acute and delayed antithrombotic effects of alcohol in humans Am J Cardiol 87 2001 82 85
67. K.J. Mukamal, J.M. Massaro, and K.A. Ault Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study Alcohol Clin Exp Res 29 10 2005 1906 1912
68. O. Kovich, and C.C. Otley Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation J Am Acad Dermatol 48 2003 233 237
69. M.R. Khalifeh, and R.J. Redett The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations Plast Reconstr Surg 118 5 2006 110e 117e
70. M. Alam, and L.H. Goldberg Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy Dermatol Surg 28 2002 992 998
71. C.F. Schanbacher, and R.G. Bennett Postoperative stroke after stopping warfarin for cutaneous surgery Dermatol Surg 26 2000 785 789
72. A.Y. Kirkorian, B.L. Moore, J. Siskind, and E.S. Marmur Perioperative management of anticoagulant therapy during cutaneous surgery: 2005 survey of Mohs surgeons Dermatol Surg 33 2007 1189 1197
73. O. Kovich, and C.C. Otley Perioperative management of anticoagulants and platelet inhibitors for cutaneous surgery: a survey of current practice Dermatol Surg 28 2002 513 517
74. J.S. Healey, J. Eikelboom, and J. Douketis Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial Circulation 126 2012 343 348
75. T.L. Ortel Perioperative management of patients on chronic antithrombotic therapy Blood 120 2012 4699 4705
76. A.C. Spyropoulous, and J.D. Douketis How I treat anticoagulated patients undergoing an elective procedure or surgery Blood 120 2012 2954 2962